News update
  • Chief Adviser Dr. Yunus leaves Dhaka for Davos to attend WEF     |     
  • Fertiliser crisis hits Shailkupa Onion farmers in peak season     |     
  • Trump returns to power after unprecedented comeback     |     
  • US Charge d’affaires Tracey Jacobson calls on Chief Adviser     |     
  • Infections cause 20-40% of newborn deaths in BD: Study     |     

Infections cause 20-40% of newborn deaths in BD: Study

Disease 2025-01-20, 10:07pm

reports-ot-two-clinical-trials-on-child-deaths-were-presented-at-programme-at-the-redisson-blue-hotel-on-monday-0af88b9ff966b5ae8c24fc5db73c7e191737389247.jpeg

Reports ot two clinical trials on child deaths were presented at programme at the Radisson Blue Hotel on Monday



Dhaka, Jan 20 – Infections account for 20-40% of newborn deaths in Bangladesh, according to findings from two significant clinical trials.

The results were presented at the Radisson Blu Water Garden Hotel in Dhaka on Monday aiming to improve the management of potential severe bacterial infections (PSBI) in infants under two months old.

The trials, organised by the Ministry of Health and Family Welfare and the Projahnmo Research Foundation (PRF), introduced innovative approaches to treat newborn infections more effectively, particularly in low-income settings.

Speaking at the event, Professor Dr Md Sayedur Rahman, special assistant to the Chief Adviser of the Ministry of Health and Family Welfare, said, “Infections among infants under two months are a major global health issue and a significant cause of death for children under five, especially in low- and middle-income countries. Globally, an estimated 60-70% of under-five deaths occur within the first two months of life.”

Key Findings of the Clinical Trials

Approximately 8-10% of infants face at least one severe bacterial infection in their first two months.

The trials demonstrated that low-cost antibiotics, such as amoxicillin and gentamicin, are effective in treating these infections.

For low-risk infants, outpatient care or home treatment was shown to be safe and effective, reducing the need for hospitalisation.

Moderate-risk infants who responded well to a 48-hour course of injectable antibiotics could benefit from switch therapy, involving early discharge and oral antibiotics at home.

The trials, conducted with funding from the Bill and Melinda Gates Foundation, spanned six countries, including Bangladesh, Ethiopia, India, Nigeria, Pakistan, and Tanzania. They underscored the importance of reducing unnecessary hospital admissions, minimising healthcare costs, and improving overall outcomes for families.

Implications for Bangladesh and Beyond

The findings highlight a new path forward for managing newborn infections in resource-limited settings. By adopting these approaches, healthcare systems can reduce hospital-acquired infections, improve accessibility, and provide safer, cost-effective care options for families.

“Evidence-based practices like these are crucial for improving newborn healthcare and addressing one of the most pressing global health challenges,” remarked the Director General of the Directorate General of Health Services, Professor Dr Md Abu Jafar, who attended as the chief guest.

The event brought together policymakers, senior paediatricians, and stakeholders to discuss strategies for implementing the findings across Bangladesh and other low-income countries, potentially saving countless lives. - UNB